INMB - MCAP CO - INmune Bio, Inc.

INmune Bio, Inc. (INMB) focuses on neuroinflammation therapies, where the primary catalysts are the XPro1595 trials against Alzheimer's disease and its oncology portfolio. The team brings together leading immunologists, fostering an environment for independent scientific research through option programs. The market capitalization stands at 0.06. The company's price chart is available below; meanwhile, the business's environmental impact remains minimal due to outsourced manufacturing.

Market capitalization represents the aggregate value of all outstanding shares, reflecting the current market valuation of the business. This metric is calculated as the product of the price per share and the total number of shares outstanding. By analyzing the history of a company's market capitalization, an investor can see the immediate market reaction to fundamental news. For INmune Bio, Inc. (INMB), the trend of this value depends directly on the prospects of the XPro molecule. The innovative approach to treating Alzheimer's creates a strategic asset that the market assesses through the prism of future revenues.